WO2014150819A3 - Cancer biomarkers and methods of treating cancer - Google Patents

Cancer biomarkers and methods of treating cancer Download PDF

Info

Publication number
WO2014150819A3
WO2014150819A3 PCT/US2014/024316 US2014024316W WO2014150819A3 WO 2014150819 A3 WO2014150819 A3 WO 2014150819A3 US 2014024316 W US2014024316 W US 2014024316W WO 2014150819 A3 WO2014150819 A3 WO 2014150819A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
biomarkers
treating
invention concerns
Prior art date
Application number
PCT/US2014/024316
Other languages
French (fr)
Other versions
WO2014150819A2 (en
Inventor
Robert Yauch
Hartmut Koeppen
Original Assignee
Genentech, Inc.
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc., F. Hoffmann-La Roche Ag filed Critical Genentech, Inc.
Publication of WO2014150819A2 publication Critical patent/WO2014150819A2/en
Publication of WO2014150819A3 publication Critical patent/WO2014150819A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present invention concerns cancer biomarkers. In particular, the invention concerns c-met as biomarkers for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
PCT/US2014/024316 2013-03-15 2014-03-12 Biomarkers and methods of treatment WO2014150819A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361801276P 2013-03-15 2013-03-15
US61/801,276 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014150819A2 WO2014150819A2 (en) 2014-09-25
WO2014150819A3 true WO2014150819A3 (en) 2015-01-08

Family

ID=50543328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/024316 WO2014150819A2 (en) 2013-03-15 2014-03-12 Biomarkers and methods of treatment

Country Status (1)

Country Link
WO (1) WO2014150819A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031027A1 (en) * 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
WO2013036872A1 (en) * 2011-09-09 2013-03-14 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031027A1 (en) * 2010-08-31 2012-03-08 Genentech, Inc. Biomarkers and methods of treatment
WO2013036872A1 (en) * 2011-09-09 2013-03-14 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer. Drugs and Biologics.", 1 May 2007 (2007-05-01), pages 1 - 22, XP055033920, Retrieved from the Internet <URL:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf> [retrieved on 20120726] *
FAORO LEONARDO ET AL: "MET/PKC.beta. expression correlate with metastasis and inhibition is synergistic in lung cancer", JOURNAL OF CARCINOGENESIS, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 15, 1 January 2009 (2009-01-01), pages 1 - 6, XP008123497, ISSN: 1477-3163, [retrieved on 20091124], DOI: 10.4103/1477-3163.57857 *
KNUDSEN BEATRICE S ET AL: "A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings", APPLIED IMMUNOHISTOCHEMSITRY AND MOLECULAR MORPHOLOGY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 17, no. 1, 1 January 2009 (2009-01-01), pages 57 - 67, XP008100340, ISSN: 1541-2016, DOI: 10.1097/PAI.0B013E3181816AE2 *
WILLIAM E PIERCEALL ET AL: "Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic response diagnostics", ANALYTICAL CELLULAR PATHOLOGY (AMSTERDAM), 1 January 2011 (2011-01-01), Netherlands, pages 159 - 168, XP055125690, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/21677381> [retrieved on 20140627], DOI: 10.3233/ACP-2011-0014 *

Also Published As

Publication number Publication date
WO2014150819A2 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
MX2013002084A (en) Biomarkers and methods of treatment.
MX2020008976A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions.
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
MX2016012285A (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression.
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
HK1208501A1 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
BR112016024789A2 (en) Methods of treating early-stage breast cancer with trastuzumab-mcc-dm1 and pertuzumab
WO2014018563A3 (en) Methods for the treatment of cancer
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
WO2014116833A3 (en) Compositions and methods for detecting neoplasia
MX2015007185A (en) Use of eribulin in the treatment of breast cancer.
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
WO2014071067A3 (en) Treatment and diagnosis of colon cancer
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
WO2013081645A3 (en) Erbb3 mutations in cancer
WO2013132354A3 (en) Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer
WO2015013233A3 (en) Methods and compositions for the treatment and diagnosis of bladder cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14718830

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14718830

Country of ref document: EP

Kind code of ref document: A2